

# Bharat Petroleum

India | Oil & Gas | Result Update



25 January 2026

## Refining strength with balance-sheet comfort

The stock price of Bharat Petroleum Corporation (BPCL IN) has risen 6% in the past three months, outperforming benchmark Nifty Index, which was down 3%, driven by refining margin strengthening, declining LPG losses and government compensation for LPG losses. BPCL delivered a strong Q3FY26 (PAT rose 62% YoY), driven by exceptionally high refining margins, healthy marketing volumes, and continued strengthening in balance-sheet. GRMs at USD 13.3/bbl remained well above mid-cycle levels, while the government's INR 13bn LPG compensation provided earnings visibility despite INR 5bn LPG under-recoveries in Q3. With near-zero gross debt at ~INR 5bn (excluding INDAS liabilities), BPCL appears structurally stronger than in prior cycles to absorb any risk of margin normalization ahead. Per our sensitivity analysis, every USD 1/bbl drop in crude oil price would improve BPCL's FY27E EPS by INR 5.9 and every USD 1/bbl rise in GRM would improve FY27E EPS by INR 5.0.

We cut FY27E and FY28E EPS by 3% and 5%, respectively, on weaker INR. We roll-over our TP to FY28E. **We reiterate BUY** with TP retained at INR 457, offering 31% upside over CMP.

**Strong GRMs and falling LPG losses led to 54% YoY growth in EBITDA:** Q3 PAT was at INR 75.4bn, up 62% YoY (17% QoQ), and lower than our estimate of INR 89.7bn due to weaker bulk fuel margins. YoY PAT growth driven by strong GRM (+137% YoY) and 85% dip in LPG losses.

**Marketing margin dropped YoY:** Per calculations, Q3 retail diesel margin was INR 3.9/liter versus INR 5.2/liter in Q2FY26 and INR 9.3/liter in Q3FY25, and gasoline margin was INR 9.0/liter versus INR 9.5/liter in Q2FY26 and INR 12.8/liter in Q3FY25. Marketing volumes rose 5.6% YoY.

**Refining – Key driver in Q3:** Reported GRM was USD 13.3/bbl versus USD 5.6/bbl in Q3FY25 and USD 10.8/bbl in Q1FY26 (Elara estimate: USD 13.4/bbl), as key product cracks such as gasoil, gasoline and jet fuel grew 62-100% YoY. Distillate yield was impressive at ~84% versus 78% reported by HPCL. The share of high sulphur crude was ~78%, reflecting strong crude flexibility. GRM at Bina refinery was USD 18.2/bbl, at Kochi was USD 12.7/bbl, and at Mumbai was USD 11.4/bbl – the benefits of complexity were visible.

**Macro environment supportive:** Refining margins remain supported by tightness in global middle-distillate, including restrictions by the EU on Russian-linked product flows. Crude below USD 65/bbl is supportive for retail margins and LPG economics. IEA expects moderating oil demand growth and surplus supply into CY26, reducing crude price risk for OMCs.

**Reiterate Buy with TP of INR 457,** led by weak crude oil price environment and tightness in refining globally. We cut FY27E and FY28E EPS by 3% and 5%, respectively, on weaker INR. We roll-over TP to FY28E. We expect diesel margin at INR 5.2/liter in FY27E (from INR 5.7/liter) and FY27E GRM at USD 6.5/bbl (from USD 5.6/bbl). We value BPCL on FY28E P/B, assuming FY29E BVPS of INR 324 (from INR 328), 15.7% ROE (from 15.6%), 11.7% cost of equity (unchanged) and 1% long-term growth (unchanged). **Retain BUY.**

### Key Financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	4,480,831	4,402,719	4,580,600	4,723,760	4,838,411
YoY (%)	(5.3)	(1.7)	4.0	3.1	2.4
EBITDA (INR mn)	440,820	254,014	435,354	365,537	382,164
EBITDA margin (%)	9.8	5.8	9.5	7.7	7.9
Adj PAT (INR mn)	260,610	123,922	255,206	200,053	205,526
YoY (%)	1,547.3	(52.4)	105.9	(21.6)	2.7
Fully DEPS (INR)	60.1	28.6	58.8	46.1	47.4
RoE (%)	40.4	15.8	28.4	19.0	17.3
RoCE (%)	29.5	13.3	23.6	17.2	16.8
P/E (x)	5.8	12.2	5.9	7.6	7.4
EV/EBITDA (x)	4.2	7.4	4.3	5.1	4.9

Note: Pricing as on 23 January 2026; Source: Company, Elara Securities Estimate

Rating: Buy

Target Price: INR 457

Upside: 31%

CMP: INR 349

As on 23 January 2026

#### Key data

Bloomberg	BPCL IN
Reuters Code	BPCL.NS
Shares outstanding (mn)	4,339
Market cap (INR bn/USD mn)	1,515/16,473
EV (INR bn/USD mn)	1,870/20,337
ADTV 3M (INR mn/USD mn)	2,727/30
52 week high/low	388/234
Free float (%)	45

Note: as on 23 January 2026; Source: Bloomberg

#### Price chart



Source: Bloomberg

Shareholding (%)	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Promoter	53.0	53.0	53.0	53.0
% Pledge	0.0	0.0	0.0	0.0
FII	14.6	15.5	16.5	18.5
DII	23.1	22.2	21.3	19.6
Others	9.3	9.4	9.2	9.0

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(3.5)	0.9	9.7
Bharat Petroleum	5.7	2.3	32.4
NSE Mid-cap	(4.3)	(0.9)	9.8
NSE Small-cap	(11.6)	(11.9)	(0.7)

Source: Bloomberg

#### Gagan Dixit

Aviation, Chemicals, Oil & Gas

+91 22 6164 8504  
gagan.dixit@elaracapital.com

Associates  
Amogh Deshpande  
amogh.deshpande@elaracapital.com

Kartik Bhandari  
kartik.bhandari@elaracapital.com



## Financials (YE March)

<b>Income Statement (INR mn)</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
Total Revenue	4,480,831	4,402,719	4,580,600	4,723,760	4,838,411
Gross Profit	719,869	549,750	743,706	675,282	702,597
EBITDA	440,820	254,014	435,354	365,537	382,164
EBIT	373,108	181,447	357,035	281,149	291,855
Interest expense	41,489	35,914	33,120	32,585	31,851
Other income	22,347	26,847	30,087	32,284	28,157
Exceptional/ Extra-ordinary items	7,978	9,443	-	-	-
PBT	361,944	181,823	354,002	280,847	288,161
Tax	93,356	48,458	98,796	80,794	82,635
Minority interest/Associates income	-	-	-	-	-
Reported PAT	268,588	133,366	255,206	200,053	205,526
Adjusted PAT	260,610	123,922	255,206	200,053	205,526
<b>Balance Sheet (INR mn)</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
Shareholders' Equity	756,351	813,841	982,664	1,118,396	1,257,410
Minority Interest	-	-	-	-	-
Trade Payables	283,058	306,341	294,551	299,695	294,827
Provisions & Other Current Liabilities	359,021	369,708	369,708	369,708	369,708
Total Borrowings	545,991	611,006	616,006	561,006	547,006
Other long term liabilities	79,757	82,927	113,007	137,235	162,048
<b>Total liabilities &amp; equity</b>	<b>2,024,178</b>	<b>2,183,822</b>	<b>2,375,936</b>	<b>2,486,040</b>	<b>2,631,000</b>
Net Fixed Assets	1,057,981	1,138,110	1,264,087	1,429,688	1,642,240
Goodwill	12,040	12,040	12,040	12,040	12,040
Intangible assets	-	-	-	-	-
Business Investments / other NC assets	284,281	282,745	282,745	282,745	282,745
Cash, Bank Balances & treasury investments	62,864	104,756	200,645	131,457	64,878
Inventories	428,361	452,652	420,500	432,596	430,597
Sundry Debtors	83,420	93,390	94,305	94,307	93,579
Other Current Assets	95,230	100,131	101,614	103,208	104,921
<b>Total Assets</b>	<b>2,024,178</b>	<b>2,183,822</b>	<b>2,375,936</b>	<b>2,486,040</b>	<b>2,631,000</b>
<b>Cash Flow Statement (INR mn)</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
<b>Cashflow from Operations</b>	<b>302,306</b>	<b>160,873</b>	<b>351,481</b>	<b>267,840</b>	<b>288,635</b>
Capital expenditure	(96,894)	(145,947)	(204,296)	(249,990)	(302,860)
Acquisitions / divestitures	11,392	(5,293)	-	-	-
Other Business cashflow	-	-	-	-	-
<b>Free Cash Flow</b>	<b>216,804</b>	<b>9,633</b>	<b>147,185</b>	<b>17,850</b>	<b>(14,225)</b>
Cashflow from Financing	(179,685)	32,259	(51,296)	(87,038)	(52,354)
Net Change in Cash / treasury investments	37,120	41,892	95,889	(69,188)	(66,579)
<b>Key assumptions &amp; Ratios</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
Dividend per share (INR)	31.1	10.0	20.0	15.0	16.0
Book value per share (INR)	174.3	187.6	226.5	257.8	289.8
RoCE (Pre-tax) (%)	29.5	13.3	23.6	17.2	16.8
ROIC (Pre-tax) (%)	30.5	14.2	26.3	19.1	17.8
ROE (%)	40.4	15.8	28.4	19.0	17.3
Asset Turnover (x)	4.3	4.0	3.8	3.5	3.2
Net Debt to Equity (x)	0.6	0.6	0.4	0.4	0.4
Net Debt to EBITDA (x)	1.1	2.0	1.0	1.2	1.3
Interest cover (x) (EBITDA/ int exp)	10.6	7.1	13.1	11.2	12.0
Total Working capital days (WC/rev)	2.2	6.2	12.4	7.2	2.2
<b>Valuation</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
P/E (x)	5.8	12.2	5.9	7.6	7.4
P/Sales (x)	0.3	0.3	0.3	0.3	0.3
EV/ EBITDA (x)	4.2	7.4	4.3	5.1	4.9
EV/ OCF (x)	6.2	11.6	5.3	7.0	6.5
FCF Yield	11.6	0.5	7.9	1.0	(0.8)
Price to BV (x)	2.0	1.9	1.5	1.4	1.2
Dividend yield (%)	8.9	2.9	5.7	4.3	4.6

Note: Pricing as on 23 January 2026; Source: Company, Elara Securities Estimate

## Exhibit 1: Quarterly financials

YE March (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Variance
Revenue	1,189,994	1,131,358	5.2	1,049,125	13.4	1,088,876	9.3
EBITDA	116,768	75,804	54.0	97,772	19.4	131,661	(11.3)
Depr	19,723	18,042	9.3	19,516	1.1	19,906	(0.9)
Forex loss	1,674	2,730	(38.7)	5,610	(70.2)	2,319	(27.8)
EBIT	97,045	57,763	68.0	78,256	24.0	111,754	(13.2)
Interest paid	3,607	4,286	(15.9)	4,208	(14.3)	4,254	(15.2)
Other income	7,501	8,285	(9.5)	11,907	(37.0)	11,380	(34.1)
Exceptional item	0	0		0		0	
PBT	100,940	61,762	63.4	85,955	17.4	118,880	(15.1)
Tax	25,487	15,270	66.9	21,530	18.4	29,140	(12.5)
Reported PAT	75,453	46,492	62.3	64,425	17.1	89,739	(15.9)
Adjusted PAT	75,453	46,492	62.3	64,425	17.1	89,739	(15.9)
EPS (INR)	17.7	10.9	62.3	15.1	17.1	21.1	(15.9)

Source: Company, Elara Securities Estimate

## Exhibit 2: Quarterly performance

	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)
GRM (USD/bbl)	13.3	5.6	136.6	10.8	22.9
Throughput (mn tonne)	10.5	9.5	10.2	9.8	7.0
Direct domestic sales (mn tonne)	14.1	13.4	4.8	12.7	11.0
Exports (mn tonne)	0.4	0.3	46.2	0.4	5.6

Source: Company, Elara Securities Research

## Exhibit 3: Assumption

	FY24	FY25	FY26E	FY27E	FY28E
Refining throughput (mn tonne)	39.9	40.5	41.2	41.5	43.1
GRM (USD/bbl)	14.1	6.8	9.3	6.6	6.0
Exchange rate (USD-INR)	82.8	84.6	88.4	91.6	91.6
Brent crude oil (USD/bbl)	83.0	78.9	66.4	65.0	65.0
Retail Diesel Margin (INR/lit)	4.3	6.4	6.6	5.2	5.2
Retail Gasoline Margin (INR/lit)	8.2	9.2	10.3	7.9	7.9
Marketing Sales volume Growth (%)	3.9	2.7	4.2	0.7	0.7

Source: Company, Elara Securities Estimate

## Exhibit 4: Valuation

(INR/share)	
<b>FY29E BVPS (INR/share), (A)</b>	<b>324</b>
Long-term ROE from FY29E (%), (B)	15.7
Cost of equity taken from Bloomberg (%), (C)	11.3
Long-term earnings growth rate (%), (D)	3.5
Equity value by FY29E, excluding dividend payout value (INR/share), (E) = (B-D)/(C-D) X (A)	505
Present value of equity, excluding dividend payout value (INR/share) (F) = (E) discounted by two years @ cost of equity(C)	408
Present value of dividend payout during FY26E-FY29E (INR/share), (G)	49
<b>BPCL: Target price by end-FY27E (INR/share) (H) = (F) + (G)</b>	<b>457</b>


Source: Elara Securities Estimate

## Exhibit 5: Change in estimates

(INR bn)	Earlier estimates			Revised estimates			% Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	4,415	4,467	4,588	4,581	4,724	4,838	3.7	5.8	5.5
EBITDA	424	368	388	435	366	382	2.7	(0.7)	(1.5)
EBITDAM	9.6	8.2	8.5	9.5	7.7	7.9	(9.8)	(49.9)	(55.6)
Net Profit	250	207	216	255	200	206	2.2	(3.5)	(4.9)
EPS (INR)	57.6	47.8	49.8	58.8	46.1	47.4	2.2	(3.5)	(4.9)

Source: Elara Securities Estimate

## Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
30-Oct-2023	Accumulate	396	347
30-Jan-2024	Buy	608	504
01-Mar-2024	Buy	849	623
10-May-2024	Buy	815	619
21-Jun-2024	Buy	408	308
28-Oct-2024	Buy	386	310
23-Jan-2025	Buy	354	271
02-May-2025	Buy	451	311
14-Aug-2025	Buy	427	318
03-Nov-2025	Buy	457	367

## Guide to Research Rating

<b>BUY (B)</b>	Absolute Return >+20%
<b>ACCUMULATE (A)</b>	Absolute Return +5% to +20%
<b>REDUCE (R)</b>	Absolute Return -5% to +5%
<b>SELL (S)</b>	Absolute Return < -5%

## Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website [www.elaracapital.com](http://www.elaracapital.com)

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

## Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

## Disclosures for U.S. Investors

**Rule 15a6 Disclosure:** This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "**Foreign Counterparty**"). Avior Capital Markets US LLC ("**Avior US**"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "**Exchange Act**") may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("**FINRA**") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

**Disclosures on Subject Companies:** Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/> and Investors are strongly encouraged to review this information before investing.

## Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("**Foreign Counterparty**") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("**Avior UK**"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("**Report**") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

## Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

**Analyst Certification:** In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

**Avior Capital Markets US, LLC** is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

**Avior Capital Markets International Limited** is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

**Elara Securities (India) Private Limited** is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India



**India**  
**Elara Securities (India) Private Limited**  
 One International Center, Tower 3,  
 21st Floor, Senapati Bapat Marg,  
 Elphinstone Road (West)  
 Mumbai – 400 013, India  
 Tel : +91 22 6164 8500

**Europe**  
**Elara Capital Plc.**  
 6th Floor, The Grove,  
 248A Marylebone Road,  
 London, NW1 6JZ,  
 United Kingdom  
 Tel : +44 20 7486 9733

**USA**  
**Elara Securities Inc.**  
 230 Park Avenue, Suite 2415,  
 New York, NY 10169, USA  
 Tel: +1 212 430 5870  
 Fax: +1 212 208 2501

**Asia / Pacific**  
**Elara Capital (Asia) Pte.Ltd.**  
 One Marina Boulevard,  
 Level 20,  
 Singapore 018989  
 Tel : +65 6978 4047



**Managing  
Director**

**Harendra Kumar** | harendra.kumar@elaracapital.com | +91 22 6164 8571



**Head of  
Research**

**Dr Bino Pathiparampil** | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

## Sales Team



**India**

**Hitesh Danak** - hitesh.danak@elaracapital.com - +91 22 6164 8543  
**Ashok Agarwal** - ashok.agarwal@elaracapital.com - +91 22 6164 8558  
**Himani Sanghavi** - himani.sanghavi@elaracapital.com - +91 22 6164 8586



**India, APAC &  
Australia**

**Sudhanshu Rajpal** - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508  
**Joshua Saldanha** - joshua.saldanha@elaracapital.com - +91 22 6164 8541  
**Shraddha Shrikhande** - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567  
**Suyash Maheshwari** - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



**India & UK**

**Prashin Lalvani** - prashin.lalvani@elaracapital.com - +91 22 6164 8544



**India & US**

**Karan Rathod** - karan.rathod@elaracapital.com - +91 22 6164 8570



**Corporate  
Access,  
Conference &  
Events**

**Anita Nazareth** - anita.nazareth@elaracapital.com - +91 22 6164 8520  
**Tina D'souza** - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#)

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

### Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500  
 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933  
 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236  
 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018  
 Investor Grievance Email ID: [investor.grievances@elaracapital.com](mailto:investor.grievances@elaracapital.com) - Tel. +91 22 6164 8509  
 Compliance Officer: Mr. Anand Rao - Email ID: [anand.rao@elaracapital.com](mailto:anand.rao@elaracapital.com) - Tel. +91 22 6164 8509